Surgery Partners (NASDAQ:SGRY) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Surgery Partners (NASDAQ:SGRY) posted its earnings results on Monday. The company reported $0.39 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.01, Zacks reports. Surgery Partners had a negative net margin of 2.03% and a positive return on equity of 2.85%. Surgery Partners updated its FY 2025 guidance to EPS.

Surgery Partners Price Performance

Shares of NASDAQ:SGRY opened at $24.00 on Tuesday. Surgery Partners has a 12 month low of $19.50 and a 12 month high of $33.97. The company has a current ratio of 1.80, a quick ratio of 1.66 and a debt-to-equity ratio of 0.99. The stock has a market cap of $3.05 billion, a P/E ratio of -50.00, a P/E/G ratio of 19.21 and a beta of 2.60. The company has a 50 day moving average of $23.09 and a 200 day moving average of $26.41.

Analysts Set New Price Targets

Several analysts recently commented on SGRY shares. Royal Bank of Canada reduced their target price on Surgery Partners from $49.00 to $35.00 and set an “outperform” rating on the stock in a report on Wednesday, November 20th. JPMorgan Chase & Co. cut their target price on Surgery Partners from $38.00 to $28.00 and set a “neutral” rating on the stock in a research report on Tuesday, December 3rd. Macquarie reissued an “outperform” rating and issued a $34.00 price target on shares of Surgery Partners in a research note on Tuesday, November 19th. Finally, Bank of America started coverage on Surgery Partners in a research note on Monday, December 16th. They issued a “buy” rating and a $30.00 target price for the company. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $36.56.

Insider Buying and Selling at Surgery Partners

In related news, CFO David T. Doherty sold 13,641 shares of Surgery Partners stock in a transaction on Friday, February 7th. The stock was sold at an average price of $25.61, for a total transaction of $349,346.01. Following the completion of the sale, the chief financial officer now owns 108,862 shares of the company’s stock, valued at approximately $2,787,955.82. This trade represents a 11.14 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Harrison R. Bane sold 56,315 shares of the company’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $25.64, for a total transaction of $1,443,916.60. Following the completion of the transaction, the insider now owns 107,037 shares in the company, valued at approximately $2,744,428.68. This trade represents a 34.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 96,733 shares of company stock valued at $2,480,106 in the last three months. Company insiders own 2.30% of the company’s stock.

Surgery Partners Company Profile

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.